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Abstract Recently, CLPB deficiency has been shown to
cause a genetic syndrome with cataracts, neutropenia, and 3-
methylglutaconic aciduria. Surprisingly, the neurological pre-
sentation ranges from completely unaffected to patients with
virtual absence of development. Muscular hypo- and hyperto-
nia, movement disorder and progressive brain atrophy are
frequently reported. We present the foetal, peri- and neonatal
features of 31 patients, of which five are previously unreport-
ed, using a newly developed clinical severity scoring system
rating the clinical, metabolic, imaging and other findings
weighted by the age of onset. Our data are illustrated by foetal
and neonatal videos. The patients were classified as having a
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mild (n = 4), moderate (n = 13) or severe (n = 14) disease
phenotype. The most striking feature of the severe subtype
was the neonatal absence of voluntary movements in combi-
nation with ventilator dependency and hyperexcitability. The
foetal and neonatal presentation mirrored the course of disease
with respect to survival (current median age 17.5 years in the
mild group, median age of death 35 days in the severe group),
severity and age of onset of all findings evaluated. CLPB
deficiency should be considered in neonates with absence of
voluntary movements, respiratory insufficiency and
swallowing problems, especially if associated with 3-
methylglutaconic aciduria, neutropenia and cataracts. Being
an important differential diagnosis of hyperekplexia (exagger-
ated startle responses), we advise performing urinary organic
acid analysis, blood cell counts and ophthalmological exami-
nation in these patients. The neonatal presentation of CLPB
deficiency predicts the course of disease in later life, which is
extremely important for counselling.
Keywords Hyperekplexia . Prenatal seizures . Prenatal
movement disorder . 3-methylglutaconic aciduria . Cataracts .
Neutropenia
Introduction
Recently autosomal recessive mutations in CLPB have been
shown to cause a genetic syndrome with a broad phenotypic
spectrum (MIM #616254) (Wortmann et al 2015; Saunders
et al 2015; Kanabus et al 2015; Capo-Chichi et al 2015). The
neurological presentation ranges from normal development
without intellectual deficits to a severe and progressive enceph-
alopathy associated with muscular hypertonia, progressive
brain atrophy and movement disorder. Additionally, cataracts,
neutropenia, infections and leukaemia are reported. All patients
share an elevated urinary excretion of 3-methylglutaconic acid
(3-MGA) as a characteristic biomarker.
CLPB encodes caseinolytic peptidase B homologue ClpB, a
member of the AAA+ protein family with mitochondrial local-
ization (Wortmann et al 2015). The exact function of human
ClpB remains elusive, although the bacterial homologue acts
as a chaperone involved in disaggregation of misfolded proteins
(Rosenzweig et al 2013)5. In two independent zebrafish models
of CLPB defects, neurological features (cerebellar hypoplasia,
abnormal touch-evoked response with increased swim velocity
and tail beat frequency) reflect the human phenotype
(Wortmann et al 2015; Capo-Chichi et al 2015).
In this paper we present the foetal and neonatal data of 31
CLPB deficient patients and a clinical scoring system that can
predict the further disease course based on these data.
Subjects and methods
Patients and data collection
Both the data of the previously unreported (P16, P17, P24, P25
and P31) as well as of the previously reported individuals (P1,
2, 5, 6, 7, 9, 10, 11, 18–23 are (Wortmann et al 2015) individ-
uals 1–14; P3, 4 are (Kanabus et al 2015) patients 1, 2; P12–15,
26 are (Saunders et al 2015) subjects 1–5; P8 is (Kiykim et al
2016)) were collected via an anonymized online questionnaire
completed by the respective physicians of the patients. The data
of the patients P 27–30 (individuals II-1 – II-IV, Capo-Chichi
et al 2015) were extracted from the literature. During the work
on the manuscript one additional patient was diagnosed who is
mentioned briefly in the discussion. Informed consent was ob-
tained from the parents or guardians of the children serving as
subjects of the investigation. The work described has been car-
ried out in accordance with The Code of Ethics of the World
Medical Association (Declaration of Helsinki) for experiments
involving humans.
Clinical severity scoring
For the following signs and symptoms previously reported in
CLPB deficient patients, 2 points were assigned for neonatal
onset and 1 point for onset in later life: cataracts, neutropenia,
3-MGA-uria, altered muscle tone (hyper- or hypotonia), move-
ment disorder (dystonia, tremor, ataxia etc.), seizures and brain
atrophy on MRI or autopsy. For any foetal problem, or any
APGAR score ≤ 5, 1 point was given. Additionally, the age at
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death was rated (10 points = neonatal death, 5 points = death
later in life). Intellectual disability/developmental delay was rat-
ed as follows: 0 = no, 1 = mild, 2 = moderate, 3 = severe. The
maximal score achievable was 28 points. Patients were desig-
nated as having a mild (clinical score < 5), moderate (5–15) or a
severe (> 15) phenotype. The diagnostic criteria for bedside use
can be found as Suppl. Table 1.
Foetal video ultrasound
The ultrasound videos of P23 were performed with
(Voluson E8, General Electric Healthcare, Europe). Foetal
activity and muscle tone were evaluated using the respec-
tive parameters of the biophysical profile during 20 min’
observation (Baskett et al 1987). Normal foetal activity/
gross body movements includes at least two movements
of the torso or limbs. A normal foetal muscle tone is de-
fined by at least one episode of active bending and straight-
ening of the limbs or trunk. Slow extension with return to
partial flexion, limb movement in full extension, absent
foetal movement or partially open foetal hand indicate de-
creased foetal activity and muscle tone. The presence of an
abnormal biophysical variable implies significant central
nervous system hypoxemia at the time of testing.
Genetic investigations
The alterations in CLPB (RefSeq NM_030813.3) in the pre-
viously unreported individuals were identified by exome se-
quencing followed by Sanger sequencing (P17) or directly by
Sanger sequencing (P16, 24, 25, 31) using standard proce-
dures as described previously (Wortmann et al 2015;
Saunders et al 2015; Kanabus et al 2015). Alamut® Visual
Software and the ExAC Browser (http://exac.broadinstitute.
org/) were used to interpret the variants found.
Results
Clinical details of all patients
The detailed case reports of the previously unreported (P16,
17, 24, 25, 31) patients can be found in the Supplemental data.
Supplementary Video 1 shows P16 shortly after birth and
supplementary Videos 2 and 3 show P23 as a foetus. Further
details are given below.
Clinical severity scoring (Table 1)
Four patients were classified as mild (mean clinical severity
score 3.5, range 3–4), 13 as moderate (mean score 10 range 5–
14) and 14 as having a severe phenotype (mean score 21,
range 17–26). The current median age (or age at death if
deceased) was 17.5 years (range 9–25 years, all alive) in the
mild group, 3.0 years (0.9–20 years, seven alive, six deceased)
years in the moderate group and 35 days (1 day − 3.8 years, all
deceased) in the severe phenotype (Fig. 1).
General pre- and perinatal findings (Table 2)
No prenatal abnormalities were reported in association with
the mild phenotype. Conception difficulties were reported in
17% of the moderate and 40% of the severe subgroup.
Polyhydramnios and foetal contractures were only reported
in relation with the severe phenotype (50% and 30% respec-
tively). IUGR was noted in 45% of all cases (23% of moder-
ate, 79% of severe cases). The mothers of 14% of all cases
(8% of the moderately affected and 18% of the severely af-
fected patients) reported increased foetal movements.
Decreased movements were reported for 14% of all cases
(moderate 8%, severe 27%).
A low birth weight (< p3) was noted in 20% of all and 29%
of the severely affected patients. Microcephaly (< p3) was
seen only in the severely affected subgroup (43%). Low
APGAR scores (≤ 5) were also seen predominantly in the
severe subgroup.
Neonatal features (Table 2)
The following features were most frequently reported in
the neonatal period: 3-MGA-uria, neutropenia and cata-
racts (in 74%, 52% and 28% of all patients and in
100%, 92% and 44% of the severly affected patients,
respectively).
The most frequent neonatal neurological findings in all
patients were swallowing problems (59%), burst suppression
on EEG (56%), abnormalities on neonatal brain MRI (56%)
and respiratory insufficiency (45%). The clinical presentation
shows overlap with hyperekplexia, especially in the severe
subgroup: excessive startle reflex followed by a period of
stiffness where voluntary movements are impossible were
seen in 44% of individuals. Most striking in the severe sub-
group is that all patients show an absence of voluntary move-
ments. This is mostly (86%) combined with generalized mus-
cular hypertonia, some patients show contractures at birth, and
in 79% of patients involuntary movements, ranging from limb
tremor via jitteriness to dystonia often upon tactile or acoustic
stimuli are reported. Additionally, unresponsiveness to pain
was reported in 56% of the severely affected patients.
Foetal video ultrasound
During the biophysical profile assessment of P23 at 36 weeks
gestation, no spontaneous foetal movements were seen during
20 min’ observation. The muscle tone was abnormal with
constantly bent joints of the upper and lower limbs, clenched
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hands and closed mouth. The foetus was surrounded by ex-
cessive amniotic fluid. Video 2 shows the motionless foetus
with bent elbows and clenched hands. Upon external stimula-
tion the foetus reacts with persistent high muscle tone and
excessive trembling of the upper limbs. The 3D–Video 3
shows the tense muscles of the face, including the masseter
muscle (lockjaw) as well as the clenched hands.
Genetic results of newly described patients (Table 3)
In P16 one previously reported (c.1222A > G, p.(Arg408Gly))
(Wortmann et al 2015) and one unreported variant
(c.1383dupA, p.(Asp462Arg*11)) were detected. This duplica-
tion creates a frame shift starting at codon Asp462. The new
reading frame ends in a stop codon 10 amino acids down-
stream, and the mRNA produced may be targeted for nonsense
mediated decay. Evaluation of P17 revealed two previously
reported mutations (c.1249C > T, p.(Arg417*), c.1222A > G,
p.(Arg408Gly)), and in P24 the previously reported mutation
(c.1249C > T, p.(Arg417*) was detected in homozygous state
(Wortmann et al 2015; Saunders et al 2015). Both mutations are
predicted to have deleterious impact on protein function.
A previously unreported homozygous mutation,
c.1949G > C, p.(Arg650Pro), was detected in P25. This
Table 1 Clinical severity scoring in CLPB deficient patients
Mild Moderate
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16 P17
Foetal problem 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 1 1
APGAR <5 n/a n/a n/a n/a 0 0 0 n/a n/a 0 0 n/a n/a n/a 0 0 0
Cataracts 2 2 1 1 0 1 0 n/a 1 1 0 1 1 1 n/a 1 0
Neutropenia 1 1 0 0 1 0 0 1 1 0 0 1 1 1 1 2 2
3-MGA-uria 1 1 1 1 n/a 2 2 1 1 1 1 1 1 1 n/a 2 2
Altererd muscle tone* 0 0 0 0 2 2 2 1 1 2 1 1 1 1 1 2 2
Movement disorder 0 0 0 0 1 0 0 0 1 1 1 1 1 0 0 0 2
Seizures 0 0 0 0 0 0 0 1 0 1 1 0 0 1 1 2 2
Brain atrophy n/a 0 0 n/a n/a n/a n/a 1 1 1 1 n/a 1 0 0 n/a 0
DD/ID 0 0 0 0 1 1 1 1 1 3 3 3 3 3 3 3 2
Age at death 0 0 0 0 0 0 0 0 0 0 0 5 5 5 5 0 0
Total clinical score (max 28) 4 4 3 3 5 6 6 6 7 10 8 13 14 13 11 13 13
Current age in days** 3960 3240 9000 8640 2520 1080 1080 1080 7200 6480 3600 330* 1080* 900* 1440* 4680 450
Median clinical score (range) 3.5 (3–4) 10 (5–14)
Median age (range) 17.5 (9–25) years 3 (0.9–20) years
Severe
P18 P19 P20 P21 P22 P23 P24 P25 P26 P27 P28 P29 P30 P31
Foetal problem 1 1 0 1 1 1 0 1 1 1 1 1 1 1
APGAR <5 0 1 0 1 1 1 1 0 1 1 0 1 1 1
Cataracts 1 n/a n/a 0 0 2 1 1 2 n/a n/a 0 n/a 0
Neutropenia 2 2 2 2 2 2 2 2 2 2 2 2 2 2
3-MGA-uria 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Altererd muscle tone* 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Movement disorder 1 0 2 2 2 2 2 1 2 2 2 2 2 2
Seizures 0 0 0 2 1 0 2 2 2 2 2 2 2 2
Brain atrophy 1 1 1 1 n/a n/a 1 1 2 0 0 0 0 2
DD/ID 3 3 3 3 3 3 3 3 n/a n/a n/a n/a n/a n/a
Age at death 5 5 5 5 5 10 5 5 10 10 10 10 10 10
Total clinical score (max 28) 18 17 17 21 19 25 21 20 26 22 21 22 22 24
Current age in days** (at
death)
1380* 90* 105* 150* 57* 24* 98* 45* 8* 5* 9* 4* 1* 15*
Median clinical score (range) 21 (17–26)
Median age (range) 36 days (1 day − 3.8 years)
For any of the signs and symptoms listed 2 points were given for neonatal onset, 1 point for onset in later life; with exception of foetal problems and
APGAR score (0 = no, 1 = yes), DD/ID (0 = no, 1 = mild, 2 = moderate, 3 = severe) and age at death (10 points = neonatal death, 5 points = later life).
*either decreased or increased, **at death, B = behavioural problems, DD/ID = developmental delay/intellectual disability, n/a = not available.
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variant is located in the P-loop containing nucleoside triphos-
phate hydrolase of the Clp ATPase domain. The amino acid is
highly conserved, down to zebrafish (considering 12 species).
It is evaluated as deleterious by SIFT (score 0.04, median
3.38) (Adzhubei et al 2010). P31 presented a previously un-
reported homozygous missense variant, c.1424G > A,
p.Arg(475Gln). The amino acid is highly conserved, down
to crustacean (considering nine species). None of the newly
reported variants was reported in the ExAC browser.
All parents were found to be heterozygous for one variant
each.
Genetic spectrum in all patients
A total of 22 different mutations (Table 3) were found in 31
patients from 18 families. These were 16 missense, three non-
sense and three frameshift mutations. The four nonsense mu-
tations are predicted to lead to an mRNA product prone to
nonsense mediated decay. Absence of CLPB protein in fibro-
blasts (p.(Thr268Met), p.(Ile562Thrfs*23) and in liver
(p.(Arg417*), p.(Lys321*) has been shown for the respective
mutations (Saunders et al 2015; Capo-Chichi et al 2015).
Discussion
CLPB deficiency can present with a mild, moderate
or severe phenotype
This study confirms the initial suspicion that the clinical phe-
notype of CLPB deficiency can range from mild to severe
(Wortmann et al 2015). We developed a clinical scoring sys-
tem, and based on that we describe four patients with a mild,
13 with a moderate and 14 with a severe phenotype (Table 1).
At present it is difficult to estimate which phenotype is most
frequent since ascertainment bias may favour the detection of
more severe cases. Due to the novelty of this syndrome it will
be underdiagnosed in general and especially in mildly affected
patients. Given the high frequency of conception difficulties
and miscarriages reported in parents of CLPB deficient pa-
tients, especially within the subgroup of the most severely
affected, one could speculate whether mutations in CLPB
may lead to a lethal in utero phenotype. In addition, higher
expression of CLPB transcripts observed in testicular cell
lines of both Leydig and Sertoli origin may suggest a paternal
contribution to conception difficulties (Wortmann et al 2015).
One could also speculate whether maternal haploinsufficiency
of CLPB has an influence on the foetal environment.
Genetic spectrum, genotype-phenotype correlation
CLPB deficiency is found in different ethnic backgrounds with
patients of European, Australasian and North American descent
reported. Two of the variants were found in more than one fam-
ily: p.Arg417* was reported in five families (Australia, Poland,
Turkey, Asia/Northern Europe), whereas p.Arg408Gly was
found in three families (Poland, Australia, France). In the ExaC
database this variant has only been reported in Europeans.
Nonsense and frameshift mutations are predominantly found in
the severe subgroup, whereas in patients with themild phenotype
only missense mutations are reported to date. This might indicate
a genotype-phenotype relation, where missense mutations are
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Fig. 1 Current age or age at death (*) of every patient
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associatedwith amilder phenotype, which could be explained by
partially functional CLPB protein, although in western blot anal-
ysis of fibroblast protein from patients with the missense variant
Thr268Met, no detectable CLPB protein was seen. Also, the
finding that patients with the same genotype have similar clinical
severity both within families (Tables 1 and 3, P5–7, P10–11,
P19–20, P22–23 or P27–30), and between families (P5–7 and
P17, P12–15) indicates a genotype-phenotype correlation. This
report broadens the genetic spectrum of CLPB defect by
reporting three novel mutations, one frameshift mutation
Table 2 Pre-, peri- and neonatal findings in CLPB deficient patients
Mild (n = 4) Moderate (n = 13) Severe (n = 14) All (n = 31)
Prenatal findings
Conception difficulties 0/4 (0%) 2/12 (17%) 4/10 (40%) 6/26 (23%)
Placental calcifications 1/9 (11%) 2/8 (25%) 3/21 (14%)
Altererd placental blood flow 1/9 (11%) 3/7 (43%) 4/20 (20%)
Polyhydramnios 0/13 (0%) 7/14 (50%) 7/31 (23%)
Foetal edema 1/13 (8%) 1/10 (10%) 2/27 (7%)
Foetal contractures 0/13 (0%) 3/10 (30%) 3/27 (11%)
Foetal brain abnormalities (US) 1/5 (20%) 2/9 (25%) 3/18 (17%)
Intra-uterine growth retardation 3/13 (23%) 11/14 (79%) 14/31 (45%)
Increased foetal movements 1/13 (8%) 2/11 (18%) 3/28 (11%)
Decreased foetal movements 1/13 (8%) 3/11 (27%) 4/28 (14%)
Perinatal findings
Prenatal birth 0/4 (0%) 1/13 (8%) 5/14 (36%) 6/31 (19%)
Normal vaginal delivery 4/4 (100%) 11/13 (85%) 11/14 (79%) 26/31 (84%)
Assisted delivery 0/4 (0%) 1/13 (8%) 1/14 (7%) 1/31 (3%)
Caesarean section 0/4 (0%) 1/13 (8%) 1/14 (7%) 4/31 (13%)
Birth weight < p3 2/4 (50%) 0/12 (0%) 4/14 (29%) 6/30 (20%)
Birth length < p3 0/2 (0%) 0/10 (0%) 1/9 (11%) 1/21 (48%)
Birth head circumference < p3 0/2 (0%) 0/10 (0%) 6/14 (43%) 6/26 (23%)
Apgar score 1 min <5 n/a 2/8 (25%) 10/13 (77%) 12/21 (57%)
Apgar score 5 min <5 n/a 0/8 (0%) 7/13 (54%) 7/21 (33%)
Apgar score 10 min <5 n/a 0/6 (0%) 6/9 (67%) 6/17 (35%)
Neonatal findings
3-Methylglutaconic aciduria 0/0 (0%) 4/9 (44%) 10/10 (100%) 14/19 (74%)
Neutropenia 0/2 (0%) 2/12 (17%) 12/13 (92%) 14/27 (52%)
Infection(s) 0/4 (0%) 0/13 (0%) 7/14 (50%) 7/31 (23%)
Cataracts 2/4 (50%) 1/12 (8%) 4/9 (44%) 7/25 (28%)
Jaundice 1/4 (25%) 5/13 (38%) 1/14 (7%) 7/31 (23%)
Hypoglycemia 0/4 (0%) 4/13 (31%) 2/14 (14%) 6/31 (19%)
Abnormalities on brain US 0/2 (0%) 0/4 (0%) 8/14 (57%) 8/20 (40%)
Abnormalities on brain MRI 0/2 (0%) 1/1 (100%) 8/13 (62%) 9/16 (56%)
Burst suppression on EEG 0/2 (0%) 0/1 (0%) 9/13 (69%) 9/16 (56%)
Seizures 0/4 (0%) 1/13 (8%) 4/10 (40%) 5/27 (19%)
Generalized hypertonia/stiffness 0/4 (0%) 1/13 (8%) 12/14 (86%) 13/31 (42%)
Generalized hypotonia 0/4 (0%) 4/13 (31%) 5/14 (36%) 9/31 (29%)
Excessive startle reflex, period of stiffness in
which voluntary movements are impossible
0/4 (0%) 0/12 (0%) 4/9 (44%) 4/25 (16%)
Artificial ventilation 0/4 (0%) 2/13 (15%) 12/14 (86%) 14/31 (45%)
Swallowing problems/feeding difficulties 0/4 (0%) 6/13 (46%) 10/10 (100%) 16/27 (59%)
Absence of voluntary movements 0/4 (0%) 1/13 (8%) 14/14 (100%) 15/31 (48%)
Limb tremor/ jitteriness/ involuntary movements 0/4 (0%) 2/13 (15%) 11/14 (79%) 13/31 (42%)
Unresponsiveness to pain 0/4 (0%) 1/13 (8%) 5/9 (56%) 6/25 (24%)
n/a = not available, US = ultrasound
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(leading to p.Asp462Arg*11) and two missense mutation
predicted to be pathogenic (p.Arg650Pro, p.Arg475Gln).
Pre- and perinatal findings in patients with CLPB
deficiency
Our data (Tables 1 and 2) indicate that CLPB deficiency can
lead to prenatal onset of signs and symptoms. This foetal
presentation is not reported in the mildly affected patients,
but it is frequently seen in the severely affected subgroup
where IUGR, abnormal foetal movements (both increased
and decreased), as well as polyhydramnios and contractures
were observed (Table 2, Video 2). One could speculate that the
periodically increased foetal movements represent foetal sei-
zures or the prenatal onset of a movement disorder. Decreased
foetal movements, contractures and arthrogryposis are report-
ed in neuromuscular and mitochondrial disorders, but the oc-
currence of increased movements could be indicative of
CLPB deficiency (Video 1). The finding of alterations in the
placental blood circulation are difficult to interpret in this con-
text as they represent maternal findings, but it could be spec-
ulated that CLPB haploinsufficiency plays a role.
The neonatal presentation of CLPB deficiency predicts
the clinical course in later life
In all patients, irrespective of the severity of the disease, the
most frequent neonatal findings were 3-MGA-uria, neutrope-
nia and cataracts (Table 2). Therefore, we advise urinary
organic acid screening and ophthalmological screening for
any neonate with unexplained neutropenia, especially in the
presence of neurological findings.
The findings in CLPB patients in the foetal and neonatal
period appear to predict the course of disease in later life.
This is true mainly for the neurological findings, since cataracts
do not lead to clinically important acute problems and neutro-
penia in CLPB deficiency often does not lead to corresponding
clinical problems (e.g. P1, 2, 5, 9). None of the 31 patients
reported here showed an uncomplicated neonatal period and a
severe course of disease, or vice versa. This is a very important
finding for the counselling of parents of patients diagnosed in
the future, especially as it may influence decisions concerning
continuation of intensive care treatments in the neonatal period.
The most striking feature of the severe subtype is absence of
voluntary movements in combination with ventilator depen-
dency and a hyperexcitability to tactile stimuli. Interestingly,
most patients also show unresponsiveness to pain.
CLPB mutations should be added to the differential
diagnosis of Bstiff baby^ and hyperekplexia
Several of the patients reported at the very severe end of the
spectrum show substantial clinical overlap with patients with
hyperekplexia (Thomas et al 2013). One difference is that
hyperekplexia patients are hypertonic, whereas patients with
CLPB deficiency may be hypotonic, and some may have alter-
nating periods of hypo- and hypertonia. In hyperekplexia,
glycinergic signalling is disturbed. Further investigations are
Table 3 Mutational spectrum in CLPB deficient patients
Patient Clinical severity Allele 1 Mutation type Allele 2 Mutation type
P1, 2 mild Met411Ile missense Tyr617Cys missense
P3, 4 mild Arg628Cys missense Glu639Lys missense
P5–7 moderate Arg417* nonsense Arg408Gly missense
P8 Ala269Thr missense Ala269Thr missense
P9 moderate Glu435_436delins AspPro missense Gly646Val missense
P10, 11 moderate Cys486Arg missense Cys486Arg missense
P12–15 moderate Thr268Met missense Thr268Met missense
P16 moderate Arg408Gly missense Asp462Arg*11 frameshift
P17 moderate Arg417* nonsense Arg408Gly missense
P18 severe Ala591Val missense Ala591Val missense
P19,20 severe Tyr272Cys missense Tyr272Cys missense
P21 severe Cys647Leufs*26 frame shift Ile682Asn missense
P22, 23 severe Arg417* nonsense Arg250*; Glu501Lys nonsense; missense
P24 severe Arg417* nonsense Arg417* nonsense
P25 severe Arg650Pro missense Arg650Pro missense
P26 severe Arg417* nonsense Lys321* nonsense
P27–30 severe Ile562Thrfs*23 frame shift Ile562Thrfs*23 frame shift
P31 severe Arg475Gln missense Arg475Gln missense
Previously unreported variants in bold.
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necessary to investigate the role of glycinergic signalling in
CLPB deficiency. Since CLPB deficiency should be considered
a differential diagnosis in hyperekplexia, we suggest that uri-
nary organic acid analysis, blood cell counts and ophthalmo-
logical examination are performed in all patients with a neona-
tal hyperekplexia phenotype. Identifying the underlying basis
of hyperekplexia is important for prognostication, since patients
with isolated hyperekplexia have a much more favourable out-
come than those with CLPB deficiency (Thomas et al 2013).
In conclusion, biallelic CLPB mutations show a broad
phenotypic spectrum, the hallmarks of which are 3-
methylglutaconic aciduria, neutropenia and cataracts in com-
bination with neurological findings of varying severity. CLPB
deficiency can lead to a foetal phenotype and a severe neonatal
phenotype which is quite characteristic and should be recog-
nized by neonatologists, paediatric neurologists, metabolic
physicians and geneticists. A clinical scoring system is avail-
able for predicting the clinical course based on foetal and
neonatal findings (for bedside use, see Suppl. Table 1).
During the work on this manuscript another patient has been
diagnosed with CLPB deficiency (CLPB (NM_030813.5)
c.216del (p.Arg73Alafs*168) and c.1222A > G (p.Arg408Trp),
both previously unreported). His clinical score was 5 (moderate
phenotype) which mirrors the clinical course well. Problems
started with delayed development and he learned to walk aged
5 years. He was diagnosed with 3-MGA-uria and severe chronic
neutropenia when he required ventilation for croup but has not
had recurrent infections. He is currently aged 22 years, has mild
learning difficulties and an autistic spectrum disorder with hos-
pital phobia which has precluded performance of brain MRI.
Due to the combination of fidgety movements, joint laxity and
an evolving thoracic scoliosis/kyphosis he has an abnormal gait
which compromises hiswalking. It is notable that he had an older
brother presenting with low birth weight, feeding problems and
3-MGA-uria neonatally. This sib died in his first months of sud-
den infant death syndrome (SIDS). Unfortunately no data on
neutrophil counts nor stored tissues are available to confirm if
he also suffered CLPB defect. This case could potentially illus-
trate a variability in disease severity or progression within differ-
ent siblings in the same family.
Acknowledgements Open access funding provided by Paracelsus
Medical University.
Funding The study was financially supported by Van Leersumfonds,
Koninklijke Nederlandse Akademie van Wetenschappen (project
VLF2013277 to S.B.W.), by the Dutch society for the study of inborn
errors of metabolism (ESN stimulatie beurs to S.B.W.), by Internal
Funding from the Children’s Memorial Health Institute (project S217/
12 to J.T and S136/13 to EP), by Polish National Science Centre (project
1154/B/P01/2011/40 to DP-A) and the Canadian Institutes of Health
Research (#301221 grant to C.v.K.). C.v.K. is the recipient of a scholar
award from the Michael Smith Foundation for Health Research.
Additional individual contributors Dorota Piekutowska-Abramczuk1,
Dariusz Rokicki2, Olga Fałek25, Anna Nowak26, Krystyna Brązert27,
Andrew Green28, Johannes A. Mayr29
1Department of Medical Genetics, Children’s Memorial Health Institute,
Warsaw, Poland, 2Department of Pediatrics, Nutrition and Metabolic
Diseases, Children’s Memorial Health Institute, Warsaw, Poland,
25Department of Neonatology Polish Mother’s Memorial Hospital
Research Institute, Łódź, Poland, 26Department of Neonatology,
University of Medical Sciences, Poznań, Poland, 27Department of
Neonatology, Medical University of Silesia, Zabrze, Poland, 28Department
of Clinical Genetics, Our Lady’s Children’s Hospital, Crumlin, Dublin,
Ireland, 29School of Medicine and Medical Science, University College
Dublin, Dublin, Ireland.
Compliance with ethical standards
Conflict of interest E. Pronicka, M. Ropacka-Lesiak, J. Trubicka, M.
Pajdowska, M. Linke, E. Ostergaard, C. Saunders, S. Horsch, C. van
Karnebeek, J. Yaplito-Lee, F. Distelmaier, K. Õunap, S. Rahman, M.
Castelle, J. Kelleher, S. Baris, K. Iwanicka-Pronicka, C. G. Steward, E.
Ciara, and S. B. Wortmann declare that they have no conflict of interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Adzhubei IA, Schmidt S, Peshkin L et al (2010) A method and server for
predicting damaging missense mutations. Nat Methods 7:248–249
Baskett TF, Allen AC, Gray JH, Young DC, Young LM (1987) Fetal
biophysical profile and perinatal death. Obstet Gynecol 70:357–360
Capo-Chichi JM, Boissel S, Brustein E et al (2015) Disruption of CLPB
is associated with congenital microcephaly, severe encephalopathy
and 3-methylglutaconic aciduria. J Med Genet 52:303–311
Kanabus M, Shahni R, Saldanha JW et al (2015) Bi-allelic CLPB muta-
tions cause cataract, renal cysts, nephrocalcinosis and 3-
methylglutaconic aciduria, a novel disorder of mitochondrial protein
disaggregation. J Inherit Metab Dis 38:211–219
Kiykim A, Garncarz W, Karakoc-Aydiner E, Ozen A, Kiykim E, Yesil G,
Boztug K, Baris S (2016) Novel CLPBmutation in a patient with 3-
methylglutaconic aciduria causing severe neurological involvement
and congenital neutropenia. Clin Immunol 165:1–3
Rosenzweig R, Moradi S, Zarrine-Afsar A, Glover JR, Kay LE (2013)
Unraveling the mechanism of protein disaggregation through a
ClpB-DnaK interaction. Science (New York, NY) 339:1080–1083
Saunders C, Smith L,Wibrand F et al (2015) CLPB variants associated with
autosomal-recessive mitochondrial disorder with cataract, neutropenia,
epilepsy, andmethylglutaconic aciduria. Am JHumGenet 96:258–265
Thomas RH, Chung SK, Wood SE et al (2013) Genotype-phenotype
correlations in hyperekplexia: apnoeas, learning difficulties and
speech delay. Brain J Neurol 136:3085–3095
Wortmann SB, Zietkiewicz S, Kousi M et al (2015) CLPB mutations
cause 3-methylglutaconic aciduria, progressive brain atrophy, intel-
lectual disability, congenital neutropenia, cataracts, movement dis-
order. Am J Hum Genet 96:245–257
860 J Inherit Metab Dis (2017) 40:853–860
